Mineralys Therapeutics (MLYS) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is MLYS's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

ACT Capital Partners L.P. purchased a new stake in shares of Mineralys Therapeutics, Inc. (NASDAQ: MLYS) during a recent quarter, according to its most recent filing with the SEC. The institutional investor purchased 87,…

– In the largest long-term hypertension trial of an aldosterone synthase inhibitor to date, lorundrostat demonstrated sustained reduction in automated office systolic blood pressure (AOSBP) of 17.8 mmHg at Week 48 from L…

RADNOR, Pa., Nov. 06, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

Mineralys Therapeutics is launching lorundrostat, a second-to-market ASI, with limited differentiation from BAXFENDY on efficacy or safety. MLYS faces AstraZeneca's entrenched cardiorenal franchise, restrictive payer pol…

Mineralys Therapeutics NASDAQ: MLYS is preparing to launch its hypertension drug candidate lorundrostat if it wins regulatory approval, with a U.S. Food and Drug Administration decision targeted for Dec. 22, executives s…

Mineralys Therapeutics, Inc. (MLYS) Q3 2026 Earnings Call Transcript…

– Commercialization plans for lorundrostat are on track ahead of PDUFA target date of December 22, 2026 – – New analyses from the pivotal Launch-HTN trial showed 46% of participants with uncontrolled or resistant hyperte…

RADNOR, Pa., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

RADNOR, Pa., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

- Explore-CKD met its primary endpoint; lorundrostat 25 mg once daily added to an SGLT2 inhibitor achieved a statistically significant reduction in systolic blood pressure at four weeks -…

In the large, pivotal Phase 3 Launch-HTN trial, lorundrostat achieved similar significant blood pressure reductions in participants with and without CKD, with consistent reductions across Stages 1-3 CKD…

RADNOR, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

- New analyses from the pivotal Launch-HTN trial showed that 46% of participants with difficult-to-treat hypertension receiving lorundrostat 50 mg achieved the AHA/ACC Guideline systolic blood pressure target of…

What happened Mineralys Therapeutics, Inc. (NASDAQ: MLYS) said Chief Executive Officer and director Jon Congleton sold 75,000 shares on 2026-09-30. The Form 4 says the shares changed hands at a weighted-average $25.46 ea…

RADNOR, Pa., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

RADNOR, Pa., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in c…

RADNOR, Pa., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Brian Slingsby sold 104,320 shares of the business's stock in a transaction dated Tuesday, September 22nd. The shares were sold at an average price o…

RADNOR, Pa., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

RADNOR, Pa., Sept. 23, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) insider Eric Warren sold 7,438 shares of the stock in a transaction dated Monday, September 21st. The stock was sold at an average price of $28.12, for a tota…

RADNOR, Pa., Sept. 21, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

Mineralys Therapeutics, Inc. (NASDAQ: MLYS - Get Free Report) Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $28.58, for a…

RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in …

Greenland Capital Management LP reduced its holdings in Mineralys Therapeutics, Inc. (NASDAQ: MLYS) by 64.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The ins…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

